UK's Abingdon Health expects FY26 revenue up 31%

Abingdon Health

29/07/2026 07:13

Overview
UK med-tech contract service provider expects FY26 revenue up 31% to £11.3 mln
Company achieved adjusted EBITDA profitability in H2
H2 revenue rose 63% yr/yr, driven by contract development growth

Outlook
Abingdon Health expects further growth in FY27 based on significant programmes underway
Company continues to invest in manufacturing and analytical capabilities to support future growth

Result Drivers
CONTRACT DEVELOPMENT GROWTH - H2 performance driven by significant growth in contract development (R&D) revenues
REVENUE DEFERRAL - £0.5 mln reader unit sales scheduled for H2 moved to August at the customer's request
ONGOING INVESTMENT - Continued investment in Abingdon Analytical and US manufacturing capability to support future growth

Company press release: ID:nRSc2621Oa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
 
GBP 11.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Abingdon Health PLC is GBp40.00, about 306.1% above its July 28 closing price of GBp9.85
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 41 three months ago

Reuters Recommended Reads
July 28 - France's Novacyt H1 revenue rises on SCD acquisition
July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook
July 28 - UK's Creo Medical H1 revenue rises 45%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)